Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Keytruda - What They Never Told You

Ivonescimab Topped Keytruda on Median Lung Cancer Survival by Eight Months in China but Lacks U.S. Approval

Ivonescimab beat Keytruda on survival in a China-only lung cancer trial, but the drug is not approved in the U.S. Here is what patients should know.

Medical Daily · Sep 17

Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed

Moderna and Merck's melanoma vaccine met its Phase 3 goals, but no effect size was released, and some analysts called the market reaction excessive.

Medical Daily · Aug 25

Moderna Stock Soars More Than 100% on Cancer Vaccine Breakthrough: What Investors Are Betting On

Moderna shares surged after its personalised mRNA cancer treatment met key Phase 3 trial endpoints in melanoma with Merck's Keytruda.

International Business Times UK · Aug 19

From analysis to the latest developments in health,
read the most diverse news in one place.

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Benzinga · Aug 27, 2025

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

Barchart · Aug 3, 2025

Do Wall Street Analysts Like Merck & Company Stock?

As Merck outperforms the broader market this year, Wall Street analysts remain optimistic about the stock's prospects.

Barchart · May 23, 2024

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Benzinga · Jun 29, 2022

Read news from The Economist, FT, and more,
with one subscription

Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting

The

Benzinga · Feb 25, 2022

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

Merck & Co Inc (NYSE: MRK) has

Benzinga · Jan 19, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.